Skip to main content
رجوع
PHAT logo

Phathom Pharmaceuticals, Inc.

جودة البيانات: 100%
PHAT
NASDAQ Healthcare Biotechnology
KWD 10.57
▼ KWD 0.64 (-5.71%)
القيمة السوقية: 832.90M
نطاق اليوم
KWD 10.56 KWD 11.60
نطاق 52 أسبوعًا
KWD 2.21 KWD 18.31
حجم التداول
794,084
متوسط 50 يوم / 200 يوم
KWD 12.61 / KWD 12.18
الإغلاق السابق
KWD 11.21

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E -3.8 0.4
P/B 2.9
ROE % 3.8
Net Margin % -126.4 3.9
Rev Growth 5Y % 10.0
D/E 0.2

Insider Trading Activity

20 transactions
Date Insider Type Shares Price Value
Mar 10, 2026
Parikh Asit
other 80,000
Feb 10, 2026
Cook Anne Marie
Chief Legal Off. & Corp. Sec.
grant 3,461
Feb 10, 2026
Cook Anne Marie
Chief Legal Off. & Corp. Sec.
other 1,535 KWD 12.820 KWD 19,679
Feb 10, 2026
Basta Steven L
President and CEO
grant 12,362
Feb 10, 2026
Basta Steven L
President and CEO
other 6,277 KWD 12.820 KWD 80,471
Jan 23, 2026
Parikh Asit
other 161,000
Jan 21, 2026
Breedlove Robert Charles
Principal Accounting Officer
other 776 KWD 13.610 KWD 10,561
Jan 13, 2026
Parikh Asit
other 17,500 KWD 10.300
Jan 2, 2026
Basta Steven L
President and CEO
grant 477,190
Jan 2, 2026
Narula Sanjeev
Chief Financial & Bus. Officer
grant 125,563
Dec 19, 2025
Parikh Asit
other 17,500 KWD 10.300
Dec 18, 2025
Breedlove Robert Charles
Principal Accounting Officer
other 230 KWD 16.280 KWD 3,744
Dec 17, 2025
Basta Steven L
President and CEO
other 31,502 KWD 15.360 KWD 483,871
Dec 17, 2025
Basta Steven L
President and CEO
grant 62,038
Nov 28, 2025
Basta Steven L
President and CEO
other 228,375
Nov 3, 2025
Breedlove Robert Charles
Principal Accounting Officer
sell 524 KWD 13.510 KWD 7,079
Oct 6, 2025
Narula Sanjeev
Chief Financial & Bus. Officer
grant 344,000
Sep 25, 2025
Basta Steven L
President and CEO
other 228,375
Sep 5, 2025
Breedlove Robert Charles
Principal Accounting Officer
sell 461 KWD 12.090 KWD 5,573
Jul 16, 2025
Breedlove Robert Charles
Principal Accounting Officer
sell 1,692 KWD 8.364 KWD 14,152

النقاط الرئيسية

Negative free cash flow of -166.78M
PEG of 0.13 suggests growth is underpriced
Capital efficient — spends only 0.13% of revenue on capex

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)216.93%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
N/A
ROICN/A
Net Margin-126.35%
Op. Margin-91.36%

الأمان

Debt / Equity
N/A
Current Ratio1.73
Interest Coverage-2.35

التقييم

P/E Ratio
-3.76
P/B RatioN/A
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 216.93% Revenue Growth (3Y) 1502.37%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 175.11M Net Income (TTM) -221.25M
ROE N/A ROA -85.37%
Gross Margin 87.09% Operating Margin -91.36%
Net Margin -126.35% Free Cash Flow (TTM) -166.78M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1.73
Interest Coverage -2.35 Dividend Yield 0.00%
Valuation
P/E Ratio -3.76 P/B Ratio N/A
P/S Ratio 4.76 PEG Ratio 0.13
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 832.90M Enterprise Value 705.64M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 175.11M 55.25M 682,000.0 0.0 0.0
Net Income -221.25M -334.33M -201.59M -197.72M -143.88M
EPS (Diluted) -3.03 -5.29 -3.93 -5.70 -4.00
Gross Profit 152.51M 47.28M 515,000.0 -620,000.0 -521,000.0
Operating Income -159.99M -277.47M -167.31M -172.44M -135.08M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 259.15M 378.32M 413.84M 164.81M 189.43M
Total Liabilities 697.32M 631.90M 486.60M 239.62M 117.28M
Shareholders' Equity -438.17M -253.58M -72.76M -74.81M 72.16M
Total Debt 2.71M 554.95M 139.03M 97.07M 91.34M
Cash & Equivalents 129.97M 297.26M 381.39M 155.39M 183.26M
Current Assets 228.97M 360.13M 397.43M 160.51M 186.53M
Current Liabilities 132.04M 85.73M 38.78M 26.24M 18.92M